Lexaria Bioscience Corp. (LEXX) Revenue History
Annual and quarterly revenue from 2014 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
LEXX Revenue Growth
Revenue Breakdown (FY 2025)
LEXX's revenue distribution by segment and geography for fiscal year 2025
By Product/Segment
LEXX Revenue Analysis (2014–2025)
As of May 8, 2026, Lexaria Bioscience Corp. (LEXX) generated trailing twelve-month (TTM) revenue of $522,000, reflecting significant decline in growth of -100.0% year-over-year. The most recent quarter (Q1 2026) recorded $0 in revenue, down 100.0% sequentially.
Looking at the longer-term picture, LEXX's 5-year compound annual growth rate (CAGR) stands at +17.5%, indicating consistent double-digit revenue growth. The company achieved its highest annual revenue of $1.1 million in 2014.
Revenue diversification analysis shows LEXX's business is primarily driven by IP Licensing (99%), and B2B (1%). With over half of revenue concentrated in IP Licensing, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including ATAI (+811.8% YoY), and NRXP, LEXX has underperformed the peer group in terms of revenue growth. Compare LEXX vs ATAI →
LEXX Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| LEXXCurrent | $522,000 | -100.0% | +17.5% | -1648.0% | |
 ATAI | $308,000 | +811.8% | - | -33341.2% | |
 NRXP | $1M | - | - | -1324.4% |
LEXX Historical Revenue Data (2014–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $706K | +52.0% | $587K | 83.2% | $-11,633,373 | -1648.0% |
| 2024 | $464K | +105.2% | $383K | 82.6% | $-5,695,294 | -1226.7% |
| 2023 | $226K | -11.4% | $54K | 23.9% | $-6,534,022 | -2888.5% |
| 2022 | $255K | -64.7% | $47K | 18.3% | $-6,500,844 | -2545.4% |
| 2021 | $723K | +129.6% | $547K | 75.7% | $-5,520,597 | -763.8% |
| 2020 | $315K | +41.4% | $69K | 22.0% | $-4,128,904 | -1311.6% |
| 2019 | $223K | -48.6% | $-194,032 | -87.2% | $-4,141,979 | -1860.6% |
| 2018 | $433K | +580.9% | $406K | 93.7% | $-6,613,185 | -1526.3% |
| 2017 | $64K | +56.3% | $32K | 50.9% | $-1,923,450 | -3022.4% |
| 2016 | $41K | +177.0% | $-5,516 | -13.5% | $-1,259,617 | -3093.5% |
See LEXX's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs LEXX Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare LEXX vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonLEXX — Frequently Asked Questions
Quick answers to the most common questions about buying LEXX stock.
Is LEXX's revenue growth accelerating or slowing?
LEXX revenue declined -100.0% year-over-year, contrasting with the 5-year CAGR of +17.5%. TTM revenue fell to $522000.00. This reverses the prior growth trend.
What is LEXX's long-term revenue growth rate?
Lexaria Bioscience Corp.'s 5-year revenue CAGR of +17.5% reflects the variable expansion pattern. Current YoY growth of -100.0% is below this long-term average.
How is LEXX's revenue distributed by segment?
LEXX reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2014-2025 are available for download. Segment mix reveals concentration and diversification trends.